Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations.
Ghazali N, Feng J, Hueniken K, Khan K, Balaratnam K, Waddell TK, Yasufuku K, Pierre A, Donahoe L, Wakeam E, Cypel M, Yeung J, Keshavjee S, de Perrot M, Leighl NB, Liu G, Bradbury PA, Sacher A, Eng L, Stockley T, Tsao MS, Shepherd FA.
Ghazali N, et al. Among authors: liu g.
Ther Adv Med Oncol. 2024 Dec 23;16:17588359241308466. doi: 10.1177/17588359241308466. eCollection 2024.
Ther Adv Med Oncol. 2024.
PMID: 39734710
Free PMC article.